Caplin Point Laboratories Ltd Share Price

Pharmaceuticals

NSE: CAPLIPOINT Small Cap ISIN: INE475E01026

As on 04 June 2026 at 20:11 IST

₹1,980.30

+ 7.40

(0.38%)

Sell Buy

Caplin Point Laboratories Q1 FY26 Results:

Net profit rose 23% to ₹153 crores, compared to ₹124 crores in Q1 FY25. Total income in Q1 FY26 increased 12% to ₹533 crores from ₹477.5 crores in the same period last year.

About Caplin Point Laboratories Ltd

Caplin Point Laboratories Ltd. is a fast-growing pharmaceutical company with a significant presence in emerging markets. The company was founded in the year 1990. It operates in the pharmaceutical sector, specialising in developing, manufacturing, and marketing a wide range of pharmaceutical products. The company’s headquarters is situated in Chennai, Tamil Nadu, India. Caplin Point Laboratories offers a diverse range of products, including injectables, ophthalmic solutions, and various formulations under the WHO essential list. The company has over 4,000 product registrations globally and continues to expand its product pipeline with innovative therapies. +

Over 1 Month

13.63%

Over 6 Months

4.49%

Over 1 Year

-9.04%

Over 3 Years

158.47%

Caplin Point Laboratories Ltd Summary

Close ₹1,972.90

Open ₹1,988.10

High ₹1,993.90

Low ₹1,952.40

Volume 45,721

Net Turnover (in Cr) ₹9.01

52Wk High ₹2,395

52Wk Low ₹1,500.30

52Wk High / Low

1,500.30

2,395

Caplin Point Laboratories Ltd Fundamentals

Key Financial Data

Market Cap (in Cr) ₹14,996.35

EPS (TTM) 52.17

Book Value (BV) 269.76

Div. Yield 0.20 %

P/E (TTM) 37.85

Price/Book Value 7.32

Delivery % 48.57 %

Face Value 2

Key Ratios

PE Ratio 44.83

PB Ratio 8.95

EV to Sales 19.95

PEG Ratio 2.29

ROA 19.90

ROE 21.97

Debt-Equity -

Net Profit Margin 45.12

Operating Profit Margin 62.01

Caplin Point Laboratories Ltd Financials

Consolidated

Standalone

Yearly

Quarterly

Profit and Loss

Particulars (in ₹ Cr.)	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Total Revenue	2,033.90	1,761.04	1,522.71	1,308.16	1,084.83
Total Expenses	1,357.11	1,196.88	1,071.44	922.34	771.21
Profit Before Tax	676.78	564.43	451.35	385.82	313.62
Profit After Tax	541.09	461.42	376.99	308.45	251.43
Operating Profit After Depreciation	677.40	564.94	452.05	386.52	315.21

Balance Sheet

Particulars (in ₹ Cr.)	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Fixed Assets	550.06	452.66	280.04	288.89	305.40
Total Non Current Assets	1,073.90	805.20	639.21	438.50	349.04
Total Current Assets	2,133.95	1,892.92	1,552.19	1,297.82	1,014.57
Total Assets	3,207.85	2,698.12	2,191.40	1,736.32	1,363.61
Total Shareholder's Fund	2,850.49	2,315.71	1,880.48	1,483.93	1,185.83

Cash Flow

Particulars (in ₹ Cr.)	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Net Cash From Operating Activities	432.37	318.39	271.37	336.73	268.61
Net Cash Used In Investing Activities	-333.30	-319.18	-216.40	-376.86	-29.68
Net Cash Used In Financing Activities	-38.32	-38.07	-28.17	-40.68	-23.98

Profit and Loss

Particulars (in ₹ Cr.)	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Total Revenue	887	730.93	627.61	584.61	501.30
Total Expenses	445.33	365.19	334.46	334.30	291.36
Profit Before Tax	441.67	365.74	293.15	250.31	209.94
Profit After Tax	339.49	283.71	234.26	187.87	156.23
Operating Profit After Depreciation	441.79	365.84	293.27	250.40	210.11

Balance Sheet

Particulars (in ₹ Cr.)	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Fixed Assets	205.26	165.79	156.85	163.33	182.68
Total Non Current Assets	988.79	819.21	641.48	448.49	348.35
Total Current Assets	825.69	703.10	661.70	605.67	512.64
Total Assets	1,814.48	1,522.31	1,303.18	1,054.16	860.99
Total Shareholder's Fund	1,700.93	1,390.15	1,139.91	930.65	758.67

Cash Flow

Particulars (in ₹ Cr.)	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Net Cash From Operating Activities	195.87	111.01	157.10	230.97	294.64
Net Cash Used In Investing Activities	-138.77	-118.13	-85.67	-276.02	-3.90
Net Cash Used In Financing Activities	-38.10	-34.26	-30.42	-22.76	-3.47

Particulars (in ₹ Cr.)	2026-03	2025-12	2025-09	2025-06	2025-03
Total Revenue	600.16	542.77	534.04	510.22	502.45
Total Expenses	395.92	353.10	344.87	332.46	334.39
Profit Before Tax	213.44	203.89	201	184.46	176.67
Profit After Tax	172.88	165.86	160.23	150.76	145.28
Operating Profit after Depreciation	232.60	223.35	219.56	200.93	193.88

Particulars (in ₹ Cr.)	2026-03	2025-12	2025-09	2025-06	2025-03
Total Revenue	191.36	189.22	175.18	182.57	173.61
Total Expenses	107.77	97.50	99.33	95.96	98.57
Profit Before Tax	137.72	117.01	129	112.46	110.16
Profit After Tax	109.50	87.28	102.59	85.89	86.50
Operating Profit after Depreciation	144.67	123.45	135.07	118.64	116.29

Caplin Point Laboratories Ltd Technicals

Support and Resistance

S3 S2 S1 Pivot R1 R2 R3

S1 1,952.23

S2 1,931.57

S3 1,910.73

Pivot 1,973.07

R1 1,993.73

R2 2,014.57

R3 2,035.23

Moving Average

20 SMA 1,965.65

50 SMA 1,788.96

100 SMA 1,769.74

200 SMA 1,901.47

Caplin Point Laboratories Ltd Corporate Actions

Caplin Point Laboratories Ltd

₹4.0/Share

Announcement Date 29 May 2026

Record Date 30 May 2026

Div Yield 200%

AGM Date: 28 Sep 2021

Outcome of Board Meeting Disclosure of events pursuant to Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 - Brief Proceedings of the Thirtieth Annual General Meeting held on Tuesday September 28 2021. (As Per BSE Announcement Dated on 9/28/2021 3:24:00 AM) Pursuant to regulation 44(3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we submit herewith the details regarding the voting results (Annexure - A) of the business transacted at the 30th AGM of the Members of the Company held on Tuesday, September 28, 2021 at 10:00 a.m. We also enclose the consolidated report of the scrutinizer on remote e-voting and e-voting at the AGM (Annexure - B). A copy of the above is also available in the website of the Company. This is for your kind information and records. (As Per BSE Announcement Dated on 29.09.2021)

AGM Date: 28 Sep 2021

AGM Date: 29 Sep 2022

AGM 29/09/2022 Outcome of Board meeting & Intimation of Book Closure and Record Date pursuant to Regulation 42 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (As Per BSE Announcement dated on 05.09.2022) Dear Sir/Madam, Pursuant to Regulation 34 (1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached the Annual Report for the Financial Year 2021-22 along with Notice of 31 st Annual General Meeting of the Company. You are requested to take the above on record and oblige. Thanking you, (As Per BSE Announcement Dated 08.09.2022) Submission of Proceedings of the 31st Annual General Meeting of Caplin Point Laboratories Limited (As Per BSE Announcement Dated on 29/09/2022) Appointment of Dr R Nagendran and Mr S Deenadayalan as Independent Directors of the Company (As Per BSE Announcement dated on 30.09.2022)

AGM Date: 21 Sep 2023

Intimation of Book Closure and Record date pursuant to Regulation 42 of the SEBI Lisitng Regulations. Re-appointment of Dr.C K Gariyali (DIN 08711546) as an Independent Director of the company. Proceedings of 32nd Annual General Meeting of the Company held on 21st September 2023 (As Per BSE Announcement Dated on 21/09/2023)

AGM Date: 30 Sep 2024

33rd Annual General Meeting (AGM) to be held on September 30, 2024. Details of Proceedings of the Thirty Third Annual General Meeting of the Company is attached herewith (As per BSE Announcement dated on 30/09/2024) The Voting results along with the scrutinizers report is enclosed (As Per BSE Announcement Dated on: 01/10/2024)

AGM Date: 22 Sep 2025

Approved the convening of the 34th Annual General Meeting of the Company on 22nd September, 2025 through Video Conferencing / Other Audio-Visual means Proceedings of 34th Annual General Meeting of the Company (As per BSE Announcement dated on: 22.09.2025)

Caplin Point Laboratories Ltd Peer Comparison

Company	Price	Market Cap (in Cr)
Sun Pharmaceutical Industries Ltd	₹1,789.45	₹4,29,349
Divis Laboratories Ltd	₹6,574.90	₹1,74,542.94
Torrent Pharmaceuticals Ltd	₹4,369.50	₹1,47,883.74
Cipla Ltd	₹1,375.05	₹1,11,076.61
Zydus Lifesciences Ltd	₹1,076.45	₹1,08,316.06

Caplin Point Laboratories Ltd Top Mutal Funds Invested

Fund Name	AUM
UTI-Healthcare Fund	2.17%
UTI Multi Cap Fund	1.37%
UTI-Small Cap Fund	1.32%
Quantum Small Cap Fund	1.08%
UTI-Large & Mid Cap Fund	0.93%

Caplin Point Laboratories Ltd News

Caplin Steriles receives USFDA approval for Foscarnet Sodium Injection

15 May 2026, 01:24 pm

Board of Caplin Point Laboratories recommends interim dividend

Of Rs 4 per share

14 May 2026, 03:46 pm

Caplin Point Laboratories to convene board meeting

On 14 May 2026

08 May 2026, 11:19 am

Caplin Point gains as arm gets USFDA nod for Calcium Gluconate Injection ANDA

Caplin Point Laboratories rose 2.61% to Rs 1,787.45 after its subsidiary Caplin Steriles received final USFDA approval for its Abbreviated New Drug Application (ANDA) for Calcium Gluconate Injection USP (100 mg/mL in 10 mL, 50 mL and 100 mL vials).

06 May 2026, 11:52 am

Caplin receives USFDA approval for Desmopressin Acetate Injection

28 Feb 2026, 11:56 am

Caplin Point Laboratories Ltd Stock Analysis

Annual revenue for Caplin Point Laboratories Ltd increased by 21.35% to ₹887 crore in FY 2025 from ₹730.93 crore in FY 2024.
Annual Net Profit for Caplin Point Laboratories Ltd increased by 19.66% to ₹339.49 crore in FY 2025 from ₹283.71 crore in FY 2024.
Promoter Shareholding in Caplin Point Laboratories Ltd remains unchanged by 0.00% in the most recent quarter, from 70.57% in December 2025 to 70.57% in March 2026.
Caplin Point Laboratories Ltd delivered a 1-year return of -9.04% compared to the Nifty 50, which provided a return of -4.63% as of the last trading session.
Caplin Point Laboratories Ltd share price moved up by 0.38% from its previous close of INR ₹1,972.90. The latest Caplin Point Laboratories Ltd share price is INR ₹1,980.30.
Caplin Point Laboratories Ltd share price today has been at a low of 1,950 and a high of 2,002.40. Over the past 52 weeks, the Caplin Point Laboratories Ltd share price has seen a low of 1,500.30 and a high of 2,395.

About Caplin Point Laboratories Ltd

Caplin Point Laboratories Ltd. is a fast-growing pharmaceutical company with a significant presence in emerging markets. Established in 1990, the company initially focused on manufacturing ointments and creams. It specialises in producing other external applications as well. Over the years, it has expanded its product range and market reach, becoming a key player in the pharmaceutical industry.
Caplin Point Laboratories operates in the pharmaceutical sector, specialising in developing, manufacturing, and marketing a wide range of pharmaceutical products. These include finished formulations, active pharmaceutical ingredients (APIs), and injectables. The company has a strong presence in Latin America and Francophone Africa. It has recently entered regulated markets like the United States and the European Union.
With many years of experience, Caplin Point Laboratories has built a robust business model. This model caters predominantly to the bottom of the pyramid in the areas of its presence. The company’s headquarters is located in Chennai, Tamil Nadu, India. This strategic location supports its extensive operations and distribution networks across various regions.
The promoters of Caplin Point Laboratories include P Vijayalakshmi with a 24.71% stake in the company. C C Paarthipan serves as the Chairman of the company. A team of professional managerial promoters manages the operations of the company-

Sridhar Ganesan
R Nagendran
S Deenadayalan
D Sathyanarayanan

Caplin Point Laboratories offers diverse products, including injectables and ophthalmic solutions. It also provides various formulations under the WHO essential list. The company has over 4,000 product registrations globally. It continues to expand its product pipeline with innovative therapies. These products cater to various therapeutic areas, including psychiatric, neuropsychiatric, and oncology.
While Caplin Point Laboratories is a significant player in the pharmaceutical sector, it does not hold the number one position regarding market share or market capitalization. However, its unique business model and focus on emerging markets have positioned it as a key competitor in the industry. The registered office of Caplin Point Laboratories is in Perungudi, Chennai. The registrar's office is located on Ramakrishna Street, Chennai.

The vision of Caplin Point Laboratories Limited

Caplin Point Laboratories Ltd. envisions becoming a global leader in the pharmaceutical industry, focusing on innovation, quality, and accessibility. The company’s vision is rooted in its commitment to providing affordable healthcare solutions to underserved markets. This vision drives every aspect of its operations, from research and development to manufacturing. It also influences distribution strategies, ensuring accessibility to underserved markets.
The company aims to expand its presence in regulated markets like the United States and the European Union. This expansion is part of its strategy to diversify its market base and enhance its global footprint.
Innovation is at the heart of Caplin Point Laboratories’ vision. The company invests heavily in research and development to create new and effective pharmaceutical products. This focus on innovation helps the company stay ahead of industry trends and meet the evolving needs of patients. The company’s R&D efforts focus on developing complex generics and speciality products with high market potential.
Quality is another cornerstone of Caplin Point Laboratories’ vision. The company adheres to stringent quality control measures at every stage of production. This commitment to quality ensures that its products are safe, effective, and reliable.
Caplin Point Laboratories also envisions making healthcare accessible to all. The company focuses on emerging markets, where access to affordable healthcare is often limited. By providing cost-effective pharmaceutical solutions, the company aims to improve the quality of life for people in these regions. This focus on accessibility aligns with the company’s mission to serve the bottom of the pyramid.
Sustainability is a key aspect of Caplin Point Laboratories’ vision. The company is committed to conducting its operations in an environmentally responsible manner. This includes minimizing waste, reducing energy consumption, and implementing eco-friendly practices.
Caplin Point Laboratories’ vision also strongly emphasises corporate social responsibility (CSR). The company undertakes various CSR initiatives to improve healthcare, education, and community development.
A strong leadership team supports the company’s vision. The management is focused on driving growth and achieving the company’s strategic objectives. Their expertise and experience are crucial in steering the company towards its vision.
Caplin Point Laboratories’ vision is also reflected in its workforce. The company values its employees and invests in their development. This includes providing training and development opportunities to enhance their skills and knowledge.
The company’s vision extends to its stakeholders as well. Caplin Point Laboratories aims to create shareholder value by delivering consistent financial performance. The company’s growth strategy is focused on expanding its product portfolio, entering new markets, and enhancing operational efficiency. This approach ensures sustainable growth and long-term value creation for its stakeholders.
Caplin Point Laboratories’ vision is business growth and making a difference. The company is driven by a sense of purpose and a commitment to improving healthcare outcomes. This vision inspires the company to push boundaries, embrace challenges, and strive for excellence in everything it does.